Back to Search Start Over

Effect of a leukotriene receptor antagonist on the prevention of recurrent asthma attacks after an emergency room visit

Authors :
Tsunahiko Hirano
Kazuto Matsunaga
Masanori Nakanishi
Masakazu Ichinose
Takeshi Ikeda
Hirotaka Nakanishi
Mayu Kuroda
Yoshiaki Minakata
Takeshi Nishimoto
Toshiyuki Yamagata
Source :
Allergology International. (4):341-347
Publisher :
Japanese Society of Allergology. Production and hosting by Elsevier B.V.

Abstract

BackgroundThe efficacy of montelukast, a specific cysteinyl leukotriene receptor antagonist, in preventing recurrent asthma attacks was evaluated for post-emergency management of acute asthma exacerbation.MethodsTwenty-two patients with a history of chronic asthma whose symptoms were responsive to an inhaled β-adrenergic receptor agonist in an emergency room setting, were randomized into two groups, those with and those without montelukast (n = 11 for each group). Patients in the montelukast group received an oral dose of 10 mg montelukast before leaving the emergency room following rescue treatment with an inhaled β-adrenergic receptor agonist. Patients in both groups were instructed to use an inhaled β-adrenergic receptor agonist for shortness of breath or dyspnea in post-emergency management. Additional β-adrenergic receptor agonist use, subjective asthma symptoms, sleep impairment, additional emergency visits and/or hospitalization were monitored for 24 hours following the emergency room visit.ResultsIn the montelukast group, the need for a rescue β-adrenergic receptor agonist was significantly decreased; 54.5% of patients in the montelukast group required use of β-adrenergic receptor agonist compared with 100% in the non-montelukast group (P < 0.05). The average number of uses of a β-adrenergic receptor agonist was 2.67 ± 3.58 times/ 24 h in the montelukast group compared with 11.95 ± 3.60 times/24 h in the non-montelukast group (P < 0.01). The average subjective asthma symptom scores were significantly decreased in the montelukast group, whereas no score change occurred in the non-montelukast group. The sleep impairment score was significantly lower in the montelukast group compared with that in the non-montelukast group (P < 0.05). No patients in either group had an emergency visit or hospitalization during this period.ConclusionsThe results demonstrate that montelukast can prevent recurrent asthma exacerbations in the home environment.

Details

Language :
English
ISSN :
13238930
Issue :
4
Database :
OpenAIRE
Journal :
Allergology International
Accession number :
edsair.doi.dedup.....87bf3bd83e326e321223e4560be5672f
Full Text :
https://doi.org/10.1111/j.1440-1592.2004.00359.x